Good evening and welcome to Markets Desk, your end-of-day read on what moved the needle.
Nvidia enters the second half of two thousand twenty-six still wearing the crown in artificial intelligence silicon, but the story for investors is more nuanced than that. AMD and Intel delivered meaningful stock gains despite trailing on raw chip performance, reminding the market that second place can still be a profitable trade when the tide is rising across the whole sector.
Staying in the AI space, Elon Musk is quietly turning to natural gas to keep his data centers running, and that is drawing fire from both regulators and consumers who are watching electricity prices climb. The tension between AI's insatiable power appetite and grid capacity is no longer a background risk — it is becoming a front-page policy problem with real cost implications for the industry.
And on the biotech front, a moment that rarely happens in oncology — ten thousand physicians rose to their feet mid-presentation at a major cancer conference after Revolution Medicine showed survival data for daraxonrasib in pancreatic cancer, a disease that has resisted treatment for decades. Nearly doubling survival in that indication is the kind of result that reshapes a pipeline and puts an entire therapeutic category back on the institutional radar.
That's the tape. Markets Desk, signing off the floor.
